C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On A Novel Definition Of Progression-Free Survival (pfs) In Patients With Idiopathic Pulmonary Fibrosis (ipf): Pooled Analysis From Phase Iii Trials
Lederer, D J, Trzaskoma, B L, Kirchgassler, K-U, Kreuter, M, Swigris, J J
Published in American journal of respiratory and critical care medicine (01.01.2017)
Get full text
Published in American journal of respiratory and critical care medicine (01.01.2017)
Journal Article
C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On Breathlessness As Measured By The Ucsd-Sobq Score In Patients With Idiopathic Pulmonary Fibrosis (ipf) With Moderate Lung Function Impairment
Glassberg, M K, Wijsenbeek, M, Gilberg, F, Petzinger, U, Kirchgassler, K-U, Albera, C
Published in American journal of respiratory and critical care medicine (01.01.2017)
Get full text
Published in American journal of respiratory and critical care medicine (01.01.2017)
Journal Article
C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On All-Cause Mortality (acm) And Forced Vital Capacity (FVC) In Idiopathic Pulmonary Fibrosis (ipf) Patients With Low FVC And/or Low Dlco: Analysis Of Pooled Data From Ascend And Capacity
Nathan, S D, Costabel, U, Albera, C, Kirchgassler, K-U, Chou, W, Noble, P W
Published in American journal of respiratory and critical care medicine (01.01.2017)
Get full text
Published in American journal of respiratory and critical care medicine (01.01.2017)
Journal Article
D15 NEW THERAPIES IN ILD: Impact Of Statins On Lung Function Decline In Idiopathic Pulmonary Fibrosis (ipf)
Kreuter, M, Bonella, F, Maher, T M, Costabel, U, Spagnolo, P, Weycker, D, Kirchgassler, K-U, Kolb, M
Published in American journal of respiratory and critical care medicine (01.01.2016)
Get full text
Published in American journal of respiratory and critical care medicine (01.01.2016)
Journal Article
C38 UNDERSTANDING THERAPEUTICS IN IPF: An Open-Label, Phase Ii Study (pipf-002) Of The Safety Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis (ipf)
Gotfried, M H, Girod, C E, Antin-Ozerkis, D E, Odueyungbo, A, Hormel, P, Strombom, I, Stauffer, J L, Kirchgassler, K-U, Padilla, M L
Published in American journal of respiratory and critical care medicine (01.01.2017)
Get full text
Published in American journal of respiratory and critical care medicine (01.01.2017)
Journal Article
Health and social inequities in the Federal Republic of Germany
Get full text
Journal Article
Conference Proceeding
Effectiveness and Tolerability of 12-Week Treatment with Micronised Fenofibrate 200mg in a Drug-Monitoring Programme Involving 9884 Patients with Dyslipidaemia
Kirchg ??ssler, Klaus U., Schmitz, Helga, Bach, G??nther
Published in Clinical drug investigation (01.03.1998)
Published in Clinical drug investigation (01.03.1998)
Get full text
Journal Article
Antazida und progressionsfreies Überleben bei der idiopathischen Lungenfibrose (IPF)
Kreuter, M, Wuyts, W, Renzoni, E, Koschel, D, Maher, T, Kolb, M, Weycker, D, Kirchgaessler, KU, Herth, FJF, Costabel, U
Published in Pneumologie (09.02.2016)
Published in Pneumologie (09.02.2016)
Get full text
Conference Proceeding